D.InjuryI.PrevalenceC
Continuous vigilance is critical for monitoring potential side effects
Kapoor carefully assess each patients unique health profile, including their response to previous treatments, to determine whether Mounjaro might be more effective for weight loss and metabolic health
EU consumer rights provisions under the EU Omnibus Directive and related frameworks do not apply to Omzo's published service area
Disclosures: Rodolphe SOBESKY: Orphalan: Consultant, AbbVie: Consultant, Christophe Desterke: Nothing to Disclose, Aurelia Poujois: Nothing to Disclose, Eleonora De Martin: Nothing to Disclose, Ilias Kounis: Nothing to Disclose, Cyrille Feray: Nothing to Disclose, Jean-Charles Duclos-Vallee: Nothing to Disclose, Audrey Coilly: Nothing to Disclose 2533 CLINICAL AND LABORATORY PROFILE OF ADULT PATIENTS WITH IDIOPATHIC CHOLESTATIC LIVER DISEASE ACCORDINGTO THE PRESENCE OF MDR3 MUTATIONS Paulo Bittencourt 1 Vivian Rotman 2 Lvia Geovana Celestino 3 Antonio Ricardo Andrade 4 Liana Codes 5 Raimundo Gama 3 Raymundo Parana 6 Larissa Athayde Costa 7 Maria Ferraz 3 Gilda Porta 8 , 1 Bahiana School of Medicine and Public Health, 2 Federal University of Rio de Janeiro, 3 Federal University of Sao Paulo, 4 Federal University of Bahia, 5 Portuguese Hospital of Salvador, Bahia, 6 Instituto D'Or de Pesquisa e Ensino, 7 Mendelics Analise Genomica, 8 University of Sao Paulo School of Medicine Background: In adult patients, MDR3 deficiency has been recognized after genetic testing in up to a third of the subjects with cholestatic liver disease (CLD) of unknown cause
Observational studies and patient registries document thermoregulatory complaints in a subset of users, with symptom onset often coinciding with dose increases or early treatment weeks
